c-myc oncogene product expression and prognosis in operable breast cancer.

The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Locker, A. P., Dowle, C. S., Ellis, I. O., Elston, C. W., Blamey, R. W., Sikora, K., Evan, G., Robins, R. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247286/
https://www.ncbi.nlm.nih.gov/pubmed/2679850
_version_ 1782150949334155264
author Locker, A. P.
Dowle, C. S.
Ellis, I. O.
Elston, C. W.
Blamey, R. W.
Sikora, K.
Evan, G.
Robins, R. A.
author_facet Locker, A. P.
Dowle, C. S.
Ellis, I. O.
Elston, C. W.
Blamey, R. W.
Sikora, K.
Evan, G.
Robins, R. A.
author_sort Locker, A. P.
collection PubMed
description The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours. There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is important in the control of cellular differentiation. The other findings imply that measurement of c-myc oncoprotein levels does not yield useful prognostic information.
format Text
id pubmed-2247286
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22472862009-09-10 c-myc oncogene product expression and prognosis in operable breast cancer. Locker, A. P. Dowle, C. S. Ellis, I. O. Elston, C. W. Blamey, R. W. Sikora, K. Evan, G. Robins, R. A. Br J Cancer Research Article The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours. There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is important in the control of cellular differentiation. The other findings imply that measurement of c-myc oncoprotein levels does not yield useful prognostic information. Nature Publishing Group 1989-11 /pmc/articles/PMC2247286/ /pubmed/2679850 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Locker, A. P.
Dowle, C. S.
Ellis, I. O.
Elston, C. W.
Blamey, R. W.
Sikora, K.
Evan, G.
Robins, R. A.
c-myc oncogene product expression and prognosis in operable breast cancer.
title c-myc oncogene product expression and prognosis in operable breast cancer.
title_full c-myc oncogene product expression and prognosis in operable breast cancer.
title_fullStr c-myc oncogene product expression and prognosis in operable breast cancer.
title_full_unstemmed c-myc oncogene product expression and prognosis in operable breast cancer.
title_short c-myc oncogene product expression and prognosis in operable breast cancer.
title_sort c-myc oncogene product expression and prognosis in operable breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247286/
https://www.ncbi.nlm.nih.gov/pubmed/2679850
work_keys_str_mv AT lockerap cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT dowlecs cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT ellisio cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT elstoncw cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT blameyrw cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT sikorak cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT evang cmyconcogeneproductexpressionandprognosisinoperablebreastcancer
AT robinsra cmyconcogeneproductexpressionandprognosisinoperablebreastcancer

Ejemplares similares